xCures

Market position

xCures positions itself as the creator of a "Clinical Clarity" category sitting between EHRs, interoperability platforms and generic AI organizing tools, emphasizing verifiability and source traceability over data volume or transfer speed. It cites nearly a decade of work on oncology records as the basis for its rigor, and its Series B lead investor described it as the most compelling platform they had seen for turning fragmented medical records into actionable clinical intelligence.

The company differentiates on verifiability rather than data movement: every extracted element maps to a specific source document and page, every checklist item carries a written justification, and extraction models are validated against clinical review with published accuracy benchmarks. It also cites nearly a decade of work with millions of cancer-related medical records — which it characterizes as the most complex data in medicine — as the origin of its extraction standards, and emphasizes configurability of outputs to specific decisions rather than generic summarization.

Technology

AI-assisted retrieval, classification and extraction applied to unstructured medical records. The pipeline normalizes document formats, segments and classifies content, runs AI clinical extractors to identify contextualized clinical data, deduplicates and assembles a longitudinal patient timeline, and maps every data element back to the source document and page. Extraction models are validated against clinical review, with reported benchmarks such as 99.7% combined accuracy across 200+ comorbidity assessments and 98.7% PPV / 99.4% sensitivity for cancer diagnosis details; the company notes these come from retrospective analysis of a defined historical dataset. Data is retrieved across nationwide networks, EHRs, HIEs and QHINs, and the platform is HITRUST e1 certified and participates in TEFCA.

Go-to-market

Direct enterprise sales supported by a 30-minute demo request flow on the company website, plus channel partnerships that embed the clinical clarity layer in third-party platforms. The company supports its positioning with published accuracy benchmarks, peer-reviewed citations, press releases and its own blog and commentary.

Healthcare organizations making high-stakes decisions from patient records: provider organizations and clinicians doing chart review, diagnostics laboratories needing documentation for eligibility and reimbursement, value-based care organizations working on risk adjustment, HCC capture, HEDIS and quality reporting, consumer health organizations, and channel partners embedding the clinical data layer in their own platforms.

Geography

Headquartered at 1901 Harrison Street, Suite 1100, Oakland, CA 94612. The company states it operates across all 50 U.S. states, retrieving records from national networks and more than 550,000 U.S. care locations.

History

Founded in 2018 with an early oncology focus, xCures applied AI to large-scale cancer patient data from 2018 to 2020. In 2021 it released its first AI-assisted provider and patient portals. In 2022 it made the engine available as a turnkey solution aligned to interoperability rules within 30 days of 21st Century Cures Act requirements taking effect. By the end of 2023 the engine became condition-agnostic and was offered as a B2B platform across therapeutic areas. In 2025 the company cites broader AI adoption in healthcare expanding the engine's use, and in 2026 it describes becoming an AI-first organization, closing its Series B, surpassing $76M in total funding and establishing the Clinical Clarity Engine.

Risks & controversies

No controversies are reported in the available sources. The company's own accuracy and scale statistics carry a disclaimer that they are based on retrospective analysis of a defined historical dataset and do not guarantee future performance, and most quantitative claims originate from company-published materials rather than independent verification. Internal records list disclosed funding of $92M, which is higher than the more-than-$76M total stated in the public sources.